Briakinumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Briakinumab Usage And Synthesis

Uses

Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis[1].

IC 50

IL-12; IL-23

References

[1] Panaccione R, et, al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. DOI:10.1097/MIB.0000000000000366
[2] Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586-96. DOI:10.1056/NEJMoa1010858

Briakinumab(339308-60-0)Related Product Information

• Secukinumab
• Ixekizumab
• Brazikumab
• ibritumomab tiuxetan
• Ustekinumab
• guselkumab
• Evolocumab
• Oleclumab
• Mirikizumab
• Brodalumab